

SRD5A2 Antibody (C-Term)
Peptide-affinity purified goat antibody
Catalog # AF2925a**Specification**

SRD5A2 Antibody (C-Term) - Product Information

Application	WB, E
Primary Accession	P31213
Other Accession	NP_000339.2 , 6716 , 64677 (rat)
Reactivity	Human
Predicted	Rat, Pig, Dog
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	28407

SRD5A2 Antibody (C-Term) - Additional Information**Gene ID** 6716**Other Names**3-oxo-5-alpha-steroid 4-dehydrogenase 2, 1.3.1.22, 5 alpha-SR2, SR type 2, Steroid
5-alpha-reductase 2, S5AR 2, Type II 5-alpha reductase, SRD5A2**Dilution**

WB~~1:1000

E~~N/A

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

SRD5A2 Antibody (C-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

SRD5A2 Antibody (C-Term) - Protein Information**Name** SRD5A2**Function**

Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5- alpha-3-oxosteroids. It plays a central role in sexual

differentiation and androgen physiology.

Cellular Location

Microsome membrane; Multi-pass membrane protein. Endoplasmic reticulum membrane; Multi-pass membrane protein

Tissue Location

Expressed in high levels in the prostate and many other androgen-sensitive tissues

SRD5A2 Antibody (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

SRD5A2 Antibody (C-Term) - Images

AF2925a (1 µg/ml) staining of Human Testis lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

SRD5A2 Antibody (C-Term) - References

VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ Clin. Cancer Res. 2008 May 14 (10): 3223-9. PMID: 18483391